Ifosamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Ifosamide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
474
Registered trials
302
Result records
119
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Ifosamide can convert its Small molecule drug profile and DNA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Ifosamide (query alias: ifosfamide) |
|---|---|
| Modality / target | Small molecule drug; DNA; DNA inhibitors, DNA alkylating agents |
| Highest global status | Approved |
| Originator | Baxter International, Inc. |
| Active developers | Jiangsu Hengrui Pharmaceuticals Co., Ltd., Baxter Healthcare Corp., Baxter International, Inc. |
The MCP disease footprint includes Bone Tissue Neoplasms, Childhood Malignant Solid Neoplasm, Gonadal Tissue Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600124278 | Phase 4 | Not yet recruiting | 19 | Pathological Complete Response |
| ChiCTR2600124917 | Phase 2 | Completed | 89 | major pathological response |
| NCT07477457 | Phase 2 | Recruiting | 45 | 12-month progression free survival (PFS) (cohort 1) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Real-world outcomes of neoadjuvant concurrent chemoradiotherapy with epirubicin–ifosfamide in localized high-grade soft tissue sarcoma: A single-center retrospective series (N=57).
Not Applicable; n=57; evaluation: Positive. Reported fields: Major pathologic response(>90% necrosis) = 22.6 %
Efficacy and safety analysis of anlotinib combined with etoposide plus ifosfamide in the treatment of children and adolescents with pulmonary metastatic osteosarcoma.
Not Applicable; n=38; evaluation: Positive. Reported fields: ORR = 15.0 % ; ORR = 22.2 %
Low-dose apatinib combination with first-line chemotherapy rechallenge in advanced osteosarcoma: A single-center ambispective cohort study.
Not Applicable; n=37; evaluation: Positive. Reported fields: ORR = 21.6 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Ifosamide addresses Bone Tissue Neoplasms, Childhood Malignant Solid Neoplasm, Gonadal Tissue Neoplasms. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 119 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: DNA records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-05-26 | Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe | Approved | Financial terms not disclosed |
| 2026-03-12 | 梯瓦医药与南京正大维康达成战略合作，携手提升存达®在华可及性，进一步满足临床用药需求 | Approved | Financial terms not disclosed |
| 2025-12-22 | Handok signs Korea distribution deal for two Sanofi cancer drugs | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “DNA alkylating agent for treating cancer and tumor patients with negative p53 gene mutation or defect”. The milestone feed surfaced a patent-application signal described as “Preparation method of ifosfamide, intermediate and ifosfamide composition”. The milestone feed surfaced a patent-application signal described as “Combination treatment of an Anti-CD20/Anti-CD3 bispecific antibody and chemotherapy in ctdna high risk patients”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
